KR101434612B1 - 사이클릭 나트륨 이뇨 펩타이드 구조물 - Google Patents

사이클릭 나트륨 이뇨 펩타이드 구조물 Download PDF

Info

Publication number
KR101434612B1
KR101434612B1 KR1020087026715A KR20087026715A KR101434612B1 KR 101434612 B1 KR101434612 B1 KR 101434612B1 KR 1020087026715 A KR1020087026715 A KR 1020087026715A KR 20087026715 A KR20087026715 A KR 20087026715A KR 101434612 B1 KR101434612 B1 KR 101434612B1
Authority
KR
South Korea
Prior art keywords
aaa
amino acid
delete delete
group
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087026715A
Other languages
English (en)
Korean (ko)
Other versions
KR20090025196A (ko
Inventor
셔브 디. 샤라마
마가리타 바스토스
웨이 양
후이-지 카이
Original Assignee
팔라틴 테크놀로지스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팔라틴 테크놀로지스 인코포레이티드 filed Critical 팔라틴 테크놀로지스 인코포레이티드
Publication of KR20090025196A publication Critical patent/KR20090025196A/ko
Application granted granted Critical
Publication of KR101434612B1 publication Critical patent/KR101434612B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087026715A 2006-03-30 2007-03-30 사이클릭 나트륨 이뇨 펩타이드 구조물 Expired - Fee Related KR101434612B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74396106P 2006-03-30 2006-03-30
US74396006P 2006-03-30 2006-03-30
US60/743,960 2006-03-30
US60/743,961 2006-03-30
PCT/US2007/065645 WO2007115175A2 (en) 2006-03-30 2007-03-30 Cyclic natriuretic peptide constructs

Publications (2)

Publication Number Publication Date
KR20090025196A KR20090025196A (ko) 2009-03-10
KR101434612B1 true KR101434612B1 (ko) 2014-08-26

Family

ID=38564246

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087026715A Expired - Fee Related KR101434612B1 (ko) 2006-03-30 2007-03-30 사이클릭 나트륨 이뇨 펩타이드 구조물

Country Status (14)

Country Link
US (2) US7622440B2 (enExample)
EP (1) EP2001518B1 (enExample)
JP (1) JP5355383B2 (enExample)
KR (1) KR101434612B1 (enExample)
AU (1) AU2007233116B2 (enExample)
BR (1) BRPI0709427A2 (enExample)
CA (1) CA2647143A1 (enExample)
CO (1) CO6140040A2 (enExample)
DK (1) DK2001518T3 (enExample)
EA (1) EA016804B1 (enExample)
ES (1) ES2430323T3 (enExample)
IL (1) IL194262A (enExample)
MX (1) MX2008012663A (enExample)
WO (1) WO2007115175A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
US7964181B2 (en) * 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
EP2001518B1 (en) * 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
MX2008012649A (es) * 2006-03-30 2008-10-13 Palatin Technologies Inc Sustitutos de aminoacido para constructos peptidicos.
WO2010141845A2 (en) 2009-06-05 2010-12-09 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
UY32902A (es) * 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
CA2796725A1 (en) * 2010-04-21 2011-10-27 Palatin Technologies, Inc. Uses of natriuretic peptide constructs
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
KR101867026B1 (ko) 2011-12-28 2018-07-20 대우조선해양 주식회사 밸러스트 수 처리 시스템의 미처리 수 처리 모듈
EP3983437A1 (en) 2019-06-12 2022-04-20 Novartis AG Natriuretic peptide receptor 1 antibodies and methods of use
KR20220045206A (ko) * 2019-08-12 2022-04-12 바이오마린 파머수티컬 인크. 연장 방출형 조성물을 위한 소수성 펩티드 염

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223143A2 (en) * 1985-11-05 1987-05-27 California Biotechnology, Inc. Analogs of atrial natriuretic peptides

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251438A (en) 1979-06-14 1981-02-17 The Upjohn Company Piperazinone and piperazine polypeptides
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4496544A (en) 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4952561A (en) 1984-02-07 1990-08-28 Merck & Co., Inc. Cardiac atrial peptides
JPS60184098A (ja) 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US4618600A (en) 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
JPH0780907B2 (ja) 1984-04-19 1995-08-30 シオス・ノバ・インク 新規な心房性ナトリウム尿排泄亢進性及び血管拡張性ポリペプチド
WO1985004872A1 (en) 1984-04-24 1985-11-07 The Salk Institute For Biological Studies Atrial peptide analogs
JPH0672155B2 (ja) 1984-08-24 1994-09-14 塩野義製薬株式会社 α−ｈＡＮＰ抗血清作製用ポリペプチド
US4609725A (en) 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
DE3614833A1 (de) 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5057603A (en) 1986-01-31 1991-10-15 Merck & Co., Inc. Peptides having ANF activity
US4716147A (en) 1986-03-27 1987-12-29 Monsanto Company Synthetic airial peptides
EP0246795A3 (en) 1986-05-20 1990-04-04 Advanced Peptide Development Limited Synthetic natriuretic peptides
US5159061A (en) 1986-09-29 1992-10-27 Takeda Chemical Industries, Ltd. Atrial natriuretic peptide derivative
US4804650A (en) 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
DK531986D0 (da) 1986-11-07 1986-11-07 Novo Industri As Peptider
DE3878231T2 (de) 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
US5095004A (en) 1987-03-25 1992-03-10 Bio-Mega Inc. Fluorine containing atrial natriuretic peptides
US5376635A (en) 1987-03-15 1994-12-27 Bio-Mega/Boehringer Ingelheim Research Inc. Fluorine containing atrial natriuretic peptides
US5091366A (en) 1987-05-19 1992-02-25 Merck & Co., Inc. Peptides having ANF activity
US4816443A (en) 1987-05-19 1989-03-28 Merck & Co., Inc. Piptides having ANF activity
IL86386A0 (en) 1987-05-21 1988-11-15 Merrell Dow Pharma Novel anf derivatives
JP2544929B2 (ja) 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US5047397A (en) 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
JP2855143B2 (ja) 1987-12-24 1999-02-10 サイオス インコーポレイテッド 心房の，ナトリウム排出亢進性ペプチドの直鎖アナログ
EP0341603A3 (en) 1988-05-09 1990-07-04 Abbott Laboratories Atrial peptide derivatives
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5057495A (en) 1988-06-24 1991-10-15 Queen's University At Kingston Atrial hypotensive peptide
DK380288D0 (da) 1988-07-07 1988-07-07 Novo Industri As Hidtil ukendet peptider
AU4211989A (en) 1988-08-18 1990-03-23 California Biotechnology, Inc. Atrial natriuretic peptide clearance inhibitors
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5106834A (en) 1988-12-27 1992-04-21 G. D. Searle & Co. Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
EP0385476B2 (en) 1989-03-01 1999-09-22 SHIONOGI & CO., LTD. Physiologically active polypeptide and DNA
CA2033198A1 (en) 1989-05-24 1990-11-25 Scott D. Lucas Atrial peptide derivatives
CA2059131A1 (en) 1989-06-23 1990-12-24 Ming-Shi Chang Compositions and methods for the synthesis of natriuretic protein receptor b and methods of use
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
JPH06501950A (ja) 1990-10-11 1994-03-03 ベーリンガー　インゲルハイム　コマンディトゲゼルシャフト 環状ペプチド、その調製法およびその薬理組成物としての使用
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
JP2925391B2 (ja) 1992-01-09 1999-07-28 サントリー株式会社 Ａｒｄｓ治療用医薬組成物
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
DK0728147T3 (da) 1993-11-12 2003-06-10 Genentech Inc Receptorspecifikke atrienatriuretiske peptider
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5567662A (en) 1994-02-15 1996-10-22 The Dow Chemical Company Method of making metallic carbide powders
FR2717484A1 (fr) 1994-03-16 1995-09-22 Pf Medicament Nouveaux composés pseudo-bis-peptidiques analogues de la CCK, leur procédé de préparation, leur utilisation à titre de médicament et les compositions pharmaceutiques les comprenant .
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ZA971864B (en) 1996-03-04 1997-12-18 Scios Inc Assays and reagents for quantifying hBNP.
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
AU739469B2 (en) 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5965533A (en) 1997-05-23 1999-10-12 Baxter International Inc. Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
WO1999012576A2 (en) 1997-09-11 1999-03-18 Musc Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
US6833358B1 (en) 1998-09-28 2004-12-21 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
AU7352200A (en) 1999-09-01 2001-03-26 Regents Of The University Of California, The Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003081246A1 (en) 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
AU2003214214A1 (en) 2002-03-18 2003-10-08 Scios Inc. Method for treating congestive heart failure
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
AU2005207886A1 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
JP2008509746A (ja) 2004-08-11 2008-04-03 アルザ・コーポレーシヨン ナトリウム利尿ペプチドを経皮送達する器具および方法
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2001518B1 (en) * 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223143A2 (en) * 1985-11-05 1987-05-27 California Biotechnology, Inc. Analogs of atrial natriuretic peptides

Also Published As

Publication number Publication date
AU2007233116A1 (en) 2007-10-11
IL194262A (en) 2014-05-28
WO2007115175A2 (en) 2007-10-11
EP2001518B1 (en) 2013-07-10
CO6140040A2 (es) 2010-03-19
WO2007115175A3 (en) 2008-12-11
EA016804B1 (ru) 2012-07-30
US20070265206A1 (en) 2007-11-15
ES2430323T3 (es) 2013-11-20
KR20090025196A (ko) 2009-03-10
BRPI0709427A2 (pt) 2011-07-12
EA200802059A1 (ru) 2009-04-28
HK1134022A1 (en) 2010-04-16
MX2008012663A (es) 2008-10-13
EP2001518A2 (en) 2008-12-17
AU2007233116B2 (en) 2013-05-09
US8580747B2 (en) 2013-11-12
JP2009532384A (ja) 2009-09-10
US20100075895A1 (en) 2010-03-25
US7622440B2 (en) 2009-11-24
EP2001518A4 (en) 2009-11-04
DK2001518T3 (da) 2013-10-07
CA2647143A1 (en) 2007-10-11
JP5355383B2 (ja) 2013-11-27

Similar Documents

Publication Publication Date Title
KR101434612B1 (ko) 사이클릭 나트륨 이뇨 펩타이드 구조물
US7795221B2 (en) Linear natriuretic peptide constructs
US20120046222A1 (en) N-terminus conformationally constrained glp-1 receptor agonist compounds
CN101505784B (zh) 环状利尿钠肽构建体
TW200819139A (en) Novel analogs of vasoactive intestinal peptide
KR101393715B1 (ko) 펩타이드 구조물용 아미노산 대체물
US20170087205A1 (en) Replacement Therapy for Natriuretic Peptide Deficiencies
US8580746B2 (en) Amide linkage cyclic natriuretic peptide constructs
US8828926B2 (en) Uses of natriuretic peptide constructs
HK1134022B (en) Cyclic natriuretic peptide constructs
CN101316625A (zh) 神经肽-2受体激动剂
HK1133393B (en) Amino acid surrogates for peptidic constructs

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170719

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180718

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190821

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190821